Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in anti-TNF refractory juvenile idiopathic arthritis-associated uveitis
ISRCTN95363507Phase 2Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in juvenile idiopathic arthritis-associated uveitis (JIA-U) and cyclitis, sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Response to treatment at 12 weeks. Started Aug 2015; status: completed.
02
Drugs
tocilizumab
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)cyclitis
Beyond the preview
Go deeper on ISRCTN95363507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95363507.